Virtual Reality a Novel Screening and Treatment Aid in Attention Deficit Disorder

This study has been completed.

Sponsor:

Information provided by:

Shaare Zedek Medical Center

ClinicalTrials.gov Identifier:

NCT00364702

First received: August 15, 2006

Last updated: August 16, 2011

Last verified: July 2006

History of Changes

Purpose

Using a virtual reality program in screening and treatment of ADHD.

Condition	Intervention	Phase
ADHD	Drug: methylphenidate	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Factorial Assignment Masking: Open Label Primary Purpose: Diagnostic
Official Title:	Virtual Reality a Novel Screening and Treatment Aid in Attention Deficit Disorder

Resource links provided by NLM:

MedlinePlus related topics: Attention Deficit Hyperactivity Disorder

Drug Information available for: Methylphenidate Methylphenidate hydrochloride

U.S. FDA Resources

Further study details as provided by Shaare Zedek Medical Center:

Primary Outcome Measures:

Virtual Reality program test results


Estimated Enrollment:	40
Study Start Date:	August 2006
Study Completion Date:	July 2007
Primary Completion Date:	July 2007 (Final data collection date for primary outcome measure)

Detailed Description:

Virtual Reality is a novel program designed to imitate a real classroom environment including various distractions. It includes a head monitor to track eye movements Children aged 10-20 years with ADHD will use the program with and without methylphenidate(1 mg/kg). Their results will be compared to a control group.

Parental consent will be obtained.

Eligibility


Ages Eligible for Study:	10 Years to 20 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Clinical diagnosis of ADHD-DSM4 criteria AGE 10-20 YEARS normal neurological examination IQ>80

Exclusion Criteria:

ABNORMAL NEUROLOGICAL STATUS

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00364702

Locations


Israel
Shaari Zedek Pediatric Neurology Unit
Jerusalem, Israel, 91031

Sponsors and Collaborators

Shaare Zedek Medical Center

Investigators


Study Chair:	V. Gross, Prof/ md	Shaari Zedek Pediatric Neurology Unit

More Information

No publications provided


ClinicalTrials.gov Identifier:	NCT00364702 History of Changes
Other Study ID Numbers:	45/04
Study First Received:	August 15, 2006
Last Updated:	August 16, 2011
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Shaare Zedek Medical Center:


Virtual Reality ADHD Methylphenidate

Additional relevant MeSH terms:


Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Mental Disorders Mental Disorders Diagnosed in Childhood Methylphenidate Central Nervous System Agents Central Nervous System Stimulants Dopamine Agents	Dopamine Uptake Inhibitors Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Pharmacologic Actions Physiological Effects of Drugs Therapeutic Uses

ClinicalTrials.gov processed this record on February 25, 2015

To Top